Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia
Status:
Completed
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
To quantify the relative effectiveness, cost, and cost-effectiveness of fMDA and MDA with
DHAp against no mass treatment for reducing P. falciparum parasite prevalence, confirmed OPD
malaria case incidence and cohort infection incidence in areas of high and low malaria
transmission and in a program-relevant manner that will permit adoption and adaptation for
wider-scale deployment.
Phase:
N/A
Details
Lead Sponsor:
PATH
Collaborators:
Minister of Community Development, Mother and Child Health, Zambia Ministry of Health, Zambia Tulane University